ODN 2395 VacciGrade™

CpG ODN, class C (human / mouse) - TLR9-based adjuvant

ODN 2395 is a synthetic oligodeoxynucleotide containing unmethylated CpG motifs (CpG ODNs).  CpG ODNs are recognized by TLR9, which is expressed exclusively on human B cells and plasmocytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses.

ODN 2395 is a class C CpG ODN specific for mouse TLR9. In vivo studies have demonstrated that C-class ODNs, such ODN 2395, are very potent Th1 adjuvants.

ODN 2395 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

ODN 2395 VacciGrade™ is for research use only, not for use in humans.


Specificity: Th1 response, human / mouse
Quality: Sterile, Endotoxin level <1 EU/mg
Working concentration: 20-50 µg/mouse
Quality control:
ODN 2395 VacciGrade™ is a preclinical grade preparation of the CpG ODN 2395. It is prepared under strict aseptic conditions and is tested for the presence of endotoxins. ODN 2395 VacciGrade™ is guaranteed sterile and its endotoxin level is <1 EU/mg.
ODN 2395 sequence: 5’-tcgtcgttttcggcgc:gcgccg-3’ (22 mer)


• 1 mg of sterile lyophilized ODN 2395 VacciGrade™
• 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

ODN 2395 VacciGrade™ is shipped at room temperature and should be stored at -20°C for up to 1 year. Upon resuspension, prepare aliquots of ODN 2395  VacciGrade™ and store at -20°C. Product is stable 6 months at -20°C when properly stored. Avoid repeated freeze-thaw cycles.


Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs) have been extensively studied as adjuvants [1]. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA [2].
CpG ODNs are recognized by TLR9, which is expressed exclusively on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses [3].
Pre-clinical studies, conducted in rodents and non-human primates, and human clinical trials have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses [1].

Three types of stimulatory CpG ODNs have been identified, types A, B and C, which differ in their immune-stimulatory activities [4-5]. Furthermore, CpG ODNs activate TLR9 in a species-specific manner [6].

ODN 2395 is a type C CpG ODN specific for mouse TLR9 [7]. Type C CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides. Type C CpG ODNs are potent inducers of IFN-α from pDC and strong B cell activators [8, 9]. In vivo studies have demonstrated that type C ODNs which combine the effects of types A and B ODNs, such ODN 2395, are very potent Th1 adjuvants [10].


1. Steinhagen F. et al., 2011. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-5.
3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503.
4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J
Immunol, 31(7): 2154-63.
5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
6. Bauer S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. PNAS, 98(16):9237-42.
7. Moseman EA. et al., 2004. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 173:4433-4442.
8. Jurk M. et al., 2004. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 209(1-2):141-54.
9. Abel K. et al., 2005. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol. 12(5):606-21.
10. Vollmer J. et al., 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 34(1):251-62.


ODN 2395 VacciGrade™

Description CpG ODN, Class C (human/mouse) - TLR9 agonist
Cat. Codevac-2395-1
Unit Size1 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".